ROMA (ITALPRESS) – Regeneron, reads in a note, has announced that the European Commission (EC) has approved an alternative and more flexible administration regime for cemiplimab in all the indications currently authorized for cancers of the skin, delpolmone and uterine cervix. The approval introduces the possibility of switching to a maintenance regimen with a higher dose of cemiplimab (700 mg) administered every six weeks by intravenous infusion of 30 minutes, after an initial treatment of 12 weeks with cemiplimab 350 mg every three weeks intravenously of 30 minutes. In addition, patients who have tolerated the first cemiplimab 350 mg infusion will benefit from reduced infusion times after the same dosage, from 30 to 15 minutes. “The management of an advanced tumor requires considerable effort in terms of time and energy by patients, caregiver and clinical teams,” says Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Regeneron’s Oncology. “The European Commission’s approval of this alternative cemiplimab administration scheme reflects our commitment to developing solutions that can improve therapeutic experience and help address the practical challenges of oncological assistance. The possibility of switching to a maintenance scheme every six weeks and, for some patients, of halving the infusion times of the dose administered every three weeks, can help reduce the load associated with morefrequent visits and longer infusions, while at the same time offering greater organizational flexibility to health professionals.” cancer treatment for patients In the United States, an additional application for biological authorization (supplementary Biologics License Application, sBLA) relating to this alternative dosing scheme is currently under evaluation by the Food and Drug Administration (FDA), with a pending decision in March 2027.-photo Ipa Agency – (ITALPRESS).





